TENCON

Post-LOE

acetaminophen; butalbital

Teva

ANDAORALCAPSULE

Approved

May 1990

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

TENCON (acetaminophen; butalbital) by Teva is clinical pharmacology this combination drug product is intended as a treatment for tension headache. Approved for minor aches, pains due to: headache sore throat flu toothache the common cold temporarily reduces fever. First approved in 1990.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY This combination drug product is intended as a treatment for tension headache. It consists of a fixed combination of butalbital, acetaminophen and caffeine. The role each component plays in the relief of the complex of symptoms known as tension headache is incompletely…

Worked on TENCON at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

TENCON

Mechanism of Action

Indications (2)